06:52:13 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Navamedic är ett norskt läkemedelsbolag. Bolaget licensierar, marknadsför och säljer hälso- och farmaceutiska produkter till sjukhus, forskningsinstitut samt apotek. Största delen av produktportföljen består av renodlade läkemedel, hälsotillskott och hälsoprodukter som används för behandling av ett flertal olika patientbesvär inom dermatologi, urologi samt gynekologi. Verksamhet innehas inom den skandinaviska marknaden. Bolaget etablerades 1999 och har sitt huvudkontor i Lysaker.

Kalender

2021-11-04 Kvartalsrapport 2021-Q3
2021-08-13 Kvartalsrapport 2021-Q2
2021-06-04 Ordinarie utdelning NAVA 0.00 NOK
2021-06-03 Årsstämma 2021
2021-05-11 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-04 Ordinarie utdelning NAVA 0.00 NOK
2020-06-03 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-03-11 Extra Bolagsstämma 2020
2020-02-13 Bokslutskommuniké 2019
2019-11-01 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning NAVA 0.00 NOK
2019-05-28 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-12-20 Extra Bolagsstämma 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-06-08 Ordinarie utdelning NAVA 0.00 NOK
2018-06-07 Årsstämma 2018
2018-05-30 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-07-28 Kvartalsrapport 2017-Q2
2017-06-07 Ordinarie utdelning NAVA 0.00 NOK
2017-06-06 Årsstämma 2017
2017-05-10 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2017-01-13 Extra Bolagsstämma 2017
2016-11-11 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-06-21 Ordinarie utdelning NAVA 0.00 NOK
2016-06-20 Årsstämma 2016
2016-05-11 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-10-30 Kvartalsrapport 2015-Q3
2015-10-30 Extra Bolagsstämma 2015
2015-08-21 Kvartalsrapport 2015-Q2
2015-06-09 Ordinarie utdelning NAVA 0.00 NOK
2015-06-08 Årsstämma 2015
2015-04-28 Kvartalsrapport 2015-Q1
2015-02-27 Bokslutskommuniké 2014
2014-10-31 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-06-10 Årsstämma 2014
2014-05-06 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-11-01 Kvartalsrapport 2013-Q3
2013-08-30 Kvartalsrapport 2013-Q2
2013-06-13 Kapitalmarknadsdag 2013
2013-05-23 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-15 Bokslutskommuniké 2012
2012-02-10 Bokslutskommuniké 2011
2011-10-21 Kvartalsrapport 2011-Q3
2011-08-25 Kvartalsrapport 2011-Q2
2011-05-05 Kvartalsrapport 2011-Q1
2011-04-14 Årsstämma 2011
2011-02-04 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-26 Kvartalsrapport 2010-Q2
2010-05-05 Kvartalsrapport 2010-Q1
2010-03-25 Årsstämma 2010
2010-02-11 Bokslutskommuniké 2009
2021-06-01 09:52:11
Oslo June 1[th], 2021 - Navamedic ASA ("Navamedic", OSE: NAVA) announces the
launch of new products in the Nordics.

Medical Nutrition is a strategically important area for Navamedic and to further
strengthen our presence, we have now launched three new products in this
category. The first to be launched is Glycosade Lemon for the dietary treatment
of Glycogen Storage Disease (GSD), an inborn error of metabolism. The other two,
K.Flo and K.Yo, are both used for the dietary management of drug-resistant
epilepsy or other conditions for which a ketogenic diet is indicated.

"We are proud to announce that the addition of these new products to the
existing portfolio will enhance our strategy of delivering a complete range of
products for patients with metabolic disorders or drug-resistant epilepsy. This
will give patients who are on a very strict dietary regimens an increased choice
of options which will make the adherence to dietary treatment easier."  says
Fredrik Karlsson, KAM Medical Nutrition of Navamedic.

Navamedic has products that combine the best of cutting-edge research with the
lifestyle demands of modern living. By launching new products to meet complex
dietary treatments, Navamedic will continue to offer new product lines
throughout the year, always with the patient at the core.

The Medical Nutrition business segment is based on the sale of products for the
treatment of inborn errors of metabolism (IEM). Within Medical Nutrition,
Navamedic is a Nordic distributor of products purchased from the UK based
company Vitaflo International ltd, a subsidiary of Nestlé. Navamedic's vendor
Vitaflo has more than 30 years of experience in producing specialist nutritional
products for Inborn Errors of Metabolism (IEM).

For more information, please contact:
Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA, +46
70 257 99 71 alexander.lidmejer@navamedic.com

About Navamedic
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com